Clinical Trials Browser

Melanoma × ibrutinib × 90 days × Clear all

NCT02581930 2026-04-30

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

Phase 2 Active not recruiting

18 enrolled 10 charts

Melanoma